Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma

Melanoma Research
Benjamin Y KongMatteo S Carlino

Abstract

We report the occurrence of autoimmune hemolytic anemia in a patient receiving the anti-PD-1 monoclonal antibody, nivolumab, for metastatic melanoma in the presence of known red cell alloantibodies, despite having received prior ipilimumab without evidence of hemolysis. The patient had a history of multiple red cell alloantibodies and a positive direct antiglobulin test, identified at the time of a prior transfusion, which occurred before treatment with ipilimumab. The patient developed symptomatic warm autoimmune hemolytic anemia after four cycles of treatment with nivolumab. Clinical improvement was noted following cessation of the drug and treatment with corticosteroids. Given that there was no prior history of hemolysis, even during treatment with ipilimumab, we hypothesize that anti-PD-1 therapy disrupted peripheral tolerance, unmasking an underlying autoimmune predisposition.

References

Dec 5, 2008·Cancer Immunology, Immunotherapy : CII·Ilyssa O GordonThomas F Gajewski
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Oct 23, 2012·International Immunology·Marie-Laure ThibultDaniel Olive
Jan 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antoni RibasAxel Hauschild
Jun 10, 2014·Journal of Immunotherapy·Pauline du RusquecBrigitte Dréno
Jul 6, 2014·Journal of Medical Case Reports·Ester SimeonePaolo Antonio Ascierto

❮ Previous
Next ❯

Citations

Oct 26, 2016·Expert Review of Anticancer Therapy·Pol Specenier
Mar 30, 2017·Expert Opinion on Drug Safety·Carlo GenovaFrancesco Grossi
Feb 28, 2017·Journal for Immunotherapy of Cancer·Eileen ShiuanDouglas Johnson
Jun 25, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sébastien Le BurelOlivier Lambotte
Mar 22, 2018·Expert Review of Anticancer Therapy·Pol Specenier
Aug 2, 2018·Current Oncology Reports·David J Palmieri, Matteo S Carlino
Aug 4, 2018·Blood Advances·Merve HasanovCristhiam M Rojas Hernandez
Apr 20, 2018·BMJ Case Reports·Hira ShaikhSalman Fazal
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Iosune BaraibarEduardo Castanon
Feb 23, 2019·American Journal of Hematology·Rebecca Karp LeafDavid E Leaf
Mar 2, 2019·The Oncologist·Elizabeth J DavisDouglas B Johnson
Sep 6, 2017·Melanoma Research·Akihiko YukiTakuro Ishiguro
Apr 16, 2020·Expert Opinion on Drug Safety·Anna M Czarnecka, Piotr Rutkowski
May 17, 2019·Nature Reviews. Clinical Oncology·Filipe MartinsMichel Obeid
May 19, 2020·The Western Journal of Emergency Medicine·Brit LongAlex Koyfman
Feb 28, 2017·Journal for Immunotherapy of Cancer·Uqba KhanTarik Hadid
Oct 24, 2018·Journal for Immunotherapy of Cancer·Jaqueline GhosnMichel Obeid
Dec 8, 2019·BMJ Case Reports·Harriet Williams, Robin Aitchison
Jul 24, 2020·Oncology and Therapy·Lucy Boyce Kennedy, April K S Salama
Jul 18, 2018·Journal for Immunotherapy of Cancer·Andrew HantelThomas F Gajewski
Oct 28, 2019·BMJ Case Reports·Philippa Johnstone, Omar Khan
Aug 9, 2020·Thoracic Cancer·Yuriko UekiHaruhito Sugiyama
Jul 12, 2019·Frontiers in Oncology·Caoilfhionn ConnollyJarushka Naidoo
Aug 7, 2019·Life Sciences·Humera Memon, Bhoomika M Patel
Oct 22, 2019·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M MichotO Lambotte
Feb 12, 2021·Frontiers in Immunology·Zena N WillsmoreSophia N Karagiannis
Mar 12, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Rafaela KramerLucie Heinzerling
Jun 2, 2020·Critical Reviews in Oncology/hematology·Ioannis ParthymosMatilda Florentin
Jan 8, 2019·The Lancet Oncology·Filipe MartinsMichel Obeid
Mar 14, 2021·British Journal of Haematology·Idoroenyi AmanamMatthew Mei
Aug 28, 2021·The American Journal of Emergency Medicine·Michael J YooMichael Gottlieb
Mar 23, 2021·Yeungnam University Journal of Medicine·Dong Won Baek, Yee Soo Chae

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. Discover the latest research on AIHA here.